vusolimogene oderparepvec-wtpg
| Brand name | TUDRIQEV |
|---|---|
| Active ingredient | vusolimogene oderparepvec-wtpg |
| Strength | 10^6-10^7 PFU/mL |
| Dosage form | Suspension |
| Route | Intratumor |
| Modality | Biologic |
| FDA approval | August 2026 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.